The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round up: Summit Corp, Jubilant Energy, Solo Oil...

Tue, 06th Mar 2012 14:37

Summit Corporation, a drug research group, has reported positive data from in vivo studies in its drug discovery programme targeting Alzheimer's disease and related neurodegenerative disorders. The most recent tril has discoved a way to enable the drug to penetrate the Blood Brain Barrier and enter the central nervous system - the major challenge when developing medicines for the treatment of such diseases. Shares gained 2.54% to 15.12p. Shares in India-focused oil and gas group Jubilant Energy jumped today after announcing that one of its development wells in the already oil-producing Kharsang Field has successfully tested for oil. The KSG#61 well, the fourth of the seven phase III development wells in the field, spudded in December and was drilled to the target depth of 1,127m in January. It has now been put into production at an initial gross rate of 70 barrels of oil per day. Shares were up 6.03% at 30.75p.While Solo Oil has said that it is making progress at its Ausable Gas Recycling and Enhanced Oil Recovery project in Ontario, its joint venture partner Reef Resources has reported that the recent wet weather has caused delays to the pipelining between the existing South Airport gas well and the Ausable process facility. Operations will start back up once better ground conditions are seen, the group said. Other field activities and developments are making good progress, Solo said."Meeting the field production target of 500 bopd by end 2012 depends on successfully implementing a range of technical modifications at the Ausable Field, the import of gas from Union Gas and from the joint ventures own Airport reefs, and the full commissioning of the venturi pumping system successfully trialled in 2011 at Ausable #1," said Solo's Executive Director Neil Ritson. Shares were down 6.67% at 0.63p.Digital Learning Marketplace has sold its UK distribution rights for the TT Knowledge Force range of simulation software back to TTS Knowledge Solutions, in a move that should allow both firms to better target their own activities. The value of the sale is £127,000 of which £75,000 cash was paid at completion. The new DLM business unit now contains two subsidiaries: Intellego, a cutting edge digital learning company, and PIXELearning, a serious games, mobile apps, and role-play technology company. Shares gained 4.3% to 0.24p. US focused exploration and production company Caza Petroleum has this morning announced that it has commenced drilling an initial test well on the outfit's Sombrero prospect in the US state of New Mexico. Caza is participating for a 20% working interest and an approximate 17.12% net revenue interest under a farm-out agreement with CML.
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.